The estimated Net Worth of Frank Torti is at least $12.3 millió dollars as of 29 September 2022. Frank Torti owns over 20,000 units of Immunovant Inc stock worth over $11,427,050 and over the last 6 years he sold IMVT stock worth over $0. In addition, he makes $882,871 as Chairman of the Board at Immunovant Inc.
Sign up
Frank Torti IMVT stock SEC Form 4 insiders trading
Frank has made over 1 trades of the Immunovant Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of IMVT stock worth $116,200 on 29 September 2022.
The largest trade he's ever made was buying 20,000 units of Immunovant Inc stock on 29 September 2022 worth over $116,200. On average, Frank trades about 870 units every 0 days since 2018. As of 29 September 2022 he still owns at least 393,358 units of Immunovant Inc stock.
You can see the complete history of Frank Torti stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Frank Torti biography
Dr. Frank M. Torti M.D. serves as Chairman of the Board of the Company. Since the closing of the Business Combination in December 2019, Dr. Torti has served as Chairperson of Immunovant’s board of directors. Dr. Torti has served as the Vant Chair of RSI since January 2020. In this capacity he serves as Chairperson of the boards of directors of the biopharmaceutical companies in the Roivant family and is responsible for the operations and management of those companies. He previously served as Vant Investment Chair of RSI, from August 2018 to December 2019. Prior to joining RSI, from August 2007 to August 2018, Dr. Torti served as a Partner of New Enterprise Associates, or NEA, specializing in investments in healthcare. Prior to joining NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics from 2002 to 2005 in various capacities, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti presently serves as Chairperson of the boards of directors of Arbutus Biopharma Corp., Axovant Gene Therapies Ltd. and several private biopharmaceutical companies. He has previously served on the boards of directors of numerous development and commercial stage public and private healthcare companies, including Annexon Biosciences, Inc., Eargo Inc., Galera Therapeutics, Inc., Myovant Sciences Ltd., NeoTract, Inc., Novast Pharmaceuticals Ltd., Urovant Sciences Ltd., and others.
What is the salary of Frank Torti?
As the Chairman of the Board of Immunovant Inc, the total compensation of Frank Torti at Immunovant Inc is $882,871. There are 3 executives at Immunovant Inc getting paid more, with Peter Salzmann having the highest compensation of $8,806,830.
How old is Frank Torti?
Frank Torti is 41, he's been the Chairman of the Board of Immunovant Inc since 2019. There are 14 older and 1 younger executives at Immunovant Inc. The oldest executive at Immunovant Inc is Atul Pande, 65, who is the Independent Director.
What's Frank Torti's mailing address?
Frank's mailing address filed with the SEC is C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER, PA, 18974.
Insiders trading at Immunovant Inc
Over the last 5 years, insiders at Immunovant Inc have traded over $21,959,710 worth of Immunovant Inc stock and bought 3,433,213 units worth $88,718,319 . The most active insiders traders include Sciences Ltd. Roivant, Peter Salzmann és Julia G. Butchko. On average, Immunovant Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,150,148. The most recent stock trade was executed by Mark S. Levine on 21 August 2024, trading 3,295 units of IMVT stock currently worth $104,979.
What does Immunovant Inc do?
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
What does Immunovant Inc's logo look like?
Complete history of Frank Torti stock trades at Arbutus Biopharma Corp, Myovant Sciences Ltd, Urovant Sciences Ltd, Immunovant Inc és Axovant Gene Therapies
Immunovant Inc executives and stock owners
Immunovant Inc executives and other stock owners filed with the SEC include:
-
Peter Salzmann,
Chief Executive Officer, Director -
Pamela Connealy,
Chief Financial Officer -
Dr. Peter Salzmann M.B.A., M.D.,
CEO & Director -
Frank Torti,
Chairman of the Board -
Dr. Julia G. Butchko Ph.D.,
Chief Devel. & Technology Officer -
Andrew Fromkin,
Independent Director -
Douglas Hughes,
Independent Director -
Atul Pande,
Independent Director -
Dr. Frank M. Torti M.B.A., M.D., MBA,
Exec. Chairperson of the Board -
George Migausky,
Independent Director -
Eric Venker,
Director -
W. Bradford Middlekauff,
General Counsel -
Michael Elliott,
Chief Scientific Officer -
Julia Butchko,
Chief Development and Technology Officer -
Dr. William L. Macias M.D., Ph.D.,
Chief Medical Officer -
Lauren Schrier M.B.A.,
VP of Marketing -
Mark S. Levine,
Chief Legal Officer & Corp. Sec. -
Tom Dorney M.B.A., M.S.,
Director of Investor Relations & Strategy -
Eva Renee Barnett M.B.A.,
Chief Financial Officer -
Sciences Holdings, Llc Health,
10% owner -
Robert K Zeldin,
Chief Medical Officer -
Myrtle S Potter,
Director -
Jay S Stout,
Chief Technology Officer -
Rita Jain,
Chief Medical Officer -
William L. Macias,
Chief Medical Officer -
Eva Renee Barnett,
Chief Financial Officer -
Mark S. Levine,
Chief Legal Officer -
Sciences Ltd. Roivant,
-
Michael Geffner,
Chief Medical Officer